Furthermore, data reported that systemic treatment with PACAP proved to greatly reduce the clinical symptoms and alter the pathogenic and cytokine profiles in animal models of some autoimmune diseases such as rheumatoid arthritis, Crohn’s disease, septic shock, and multiple sclerosis [27]. Here, ADCYAP1 is linked to autoimmune disease.